Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-glutathione S-transferase] Coupled to Oxidized Polymannose) as Maintenance Treatment in Patients With Epithelial Ovarian Cancer (EOC) in Complete Remission Following First-line Chemotherapy (A) and Patients With EOC in Second Remission (B)

NCT01521143 is registered in ClinicalTrials.gov with Prima BioMed Ltd as lead sponsor.

NCT NCT01521143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01521143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-glutathione S-transferase] Coupled to Oxidized Polymannose) as Maintenance Treatment in Patients With Epithelial Ovarian Cancer (EOC) in Complete Remission Following First-line Chemotherapy (A) and Patients With EOC in Second Remission (B)
Lead sponsor
Prima BioMed Ltd
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2012
Completion date
March 31, 2015
Enrollment
91 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer